Results 1 to 10 of about 133,774 (116)
Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches
Cancer Biotherapy and Radiopharmaceuticals, 2018 The α-emitting radionuclide actinium-225 possesses nuclear properties that are highly promising for use in targeted α therapy (TAT), a therapeutic strategy that employs α particle emissions to destroy tumors.
Nikki A Thiele, Justin J Wilson
exaly +2 more sources
Cooperative braking of urban rail vehicles with Koopman model predictive control
IET Control Theory & Applications, 2023 Braking control of urban rail vehicles with multiple carriages is critical to ensure the safe operation of urban rails. However, existing decentralized braking control methods lead to the inconsistent speed and excessive coupler force among carriages ...
Dianzhu Gao +4 more
doaj +1 more source
Motion optimization for safe robot–environment interaction with force constraints
IET Control Theory & Applications, 2023 Autonomous robotics working in the uncertain environment have drawn increasing interests from researchers. Here, an issue of online motion optimization under unknown environment is considered while preserving the safety and improving the flexible ...
Yi Guo, Haohui Huang, Xinping Guan
doaj +1 more source
Coded aperture and Compton imaging for the development of 225 Ac-based radiopharmaceuticals. [PDF]
Medical Physics (Lancaster), 2022 BACKGROUND Targeted alpha-particle therapy (TAT) has great promise as a cancer treatment. Arguably the most promising TAT radionuclide that has been proposed is 225 Ac.
Emily Frame +6 more
semanticscholar +1 more source
Medical Principles and Practice, 2023 Background: Actinium-225 (Ac-225) labelled PSMA RLT has been tested recently in metastatic castration-resistant prostate cancer (mCRPC), with encouraging results.
G. Parida +3 more
semanticscholar +1 more source
Actinium-225 Targeted Agents: Where Are We Now?
Brachytherapy, 2023 α-particle targeted radionuclide therapy has shown promise for optimal cancer management, an exciting new era for brachytherapy. Alpha-emitting nuclides can have significant advantages over gamma- and beta-emitters due to their high linear energy ...
F. Mourtada +8 more
semanticscholar +1 more source
Molecular Cancer Therapeutics, 2023 Overexpression of somatostatin receptors (SSTRs), particularly SSTR2, is found in gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and subsets of other solid tumors such as small cell lung cancer (SCLC). SCLC accounts for approximately 13%-15% of
Guangzhou Han +8 more
semanticscholar +1 more source
Recent Innovations and Nano-Delivery of Actinium-225: A Narrative Review
Pharmaceutics, 2023 The actinium-225 (225Ac) radioisotope exhibits highly attractive nuclear properties for application in radionuclide therapy. However, the 225Ac radionuclide presents multiple daughter nuclides in its decay chain, which can escape the targeted site ...
S. Mdanda +4 more
semanticscholar +1 more source
Clinical Cancer Research, 2022 PURPOSE The anti-CD33 antibody lintuzumab has modest activity against acute myeloid leukemia (AML). To increase its potency, lintuzumab was conjugated to actinium-225 (225Ac), a radionuclide yielding 4 α-particles.
T. Rosenblat +11 more
semanticscholar +1 more source
In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T
European Journal of Nuclear Medicine and Molecular Imaging, 2022 Targeting the prostate-specific membrane antigen (PSMA) using lutetium-177-labeled PSMA-specific tracers has become a very promising novel therapy option for prostate cancer (PCa). The efficacy of this therapy might be further improved by replacing the β-
E. Ruigrok +9 more
semanticscholar +1 more source